Metformin er 500 mg 24 hr tablet
Pro Research Analysisby 
Searched over 200M research papers
Metformin ER 500 mg 24-Hour Tablet: Bioavailability, Pharmacokinetics, and Patient Experience
Introduction to Metformin ER 500 mg
Metformin extended-release (ER) 500 mg tablets are a widely used formulation for managing type 2 diabetes mellitus. This formulation is designed to provide a controlled release of the drug over a 24-hour period, improving patient adherence and minimizing gastrointestinal side effects compared to immediate-release (IR) formulations.
Bioavailability and Pharmacokinetics of Metformin ER
Absorption and Systemic Exposure
Metformin ER 500 mg tablets are designed to be retained in the stomach, where the polymer matrix swells in gastric fluid, allowing the drug to dissolve and diffuse over approximately 8 hours. This results in a prolonged absorption phase, with a time to maximum plasma concentration (Tmax) of around 7.5 hours, compared to 4.2 hours for the IR formulation. The systemic exposure, measured by the area under the plasma concentration-time curve (AUC), is comparable between the ER and IR formulations when administered at equivalent daily doses.
Comparative Studies and Bioequivalence
Several studies have demonstrated the bioequivalence of metformin ER tablets to their IR counterparts and other formulations. For instance, a study comparing metformin ER tablets manufactured in China and Germany found no significant differences in pharmacokinetic parameters under both fed and fasted conditions, confirming bioequivalence. Another study comparing a liquid extemporaneous formulation of metformin to the solid tablet form in children also showed similar pharmacokinetics, supporting the flexibility of metformin dosing in different patient populations.
Patient Adherence and Satisfaction
Improved Tolerability and Adherence
Metformin ER formulations have been associated with improved patient adherence and satisfaction. A postmarketing observational study in India found that patients preferred the smaller-sized metformin 500 mg prolonged-release (PR) tablets over the ER tablets due to ease of swallowing and fewer gastrointestinal side effects. The PR formulation was also associated with higher patient satisfaction and fewer reports of the "ghost pill" effect, where the tablet shell is excreted intact.
Clinical Efficacy and Safety
Clinical trials have shown that metformin ER provides effective glycemic control comparable to IR formulations. In a 24-week randomized trial, patients receiving metformin ER achieved similar reductions in glycosylated hemoglobin (HbA1c) levels as those on IR metformin, with a significant number of patients reaching the American Diabetes Association-recommended HbA1c level of <7%. Additionally, the incidence of adverse events, particularly gastrointestinal issues like nausea, was lower with the ER formulation, suggesting that it may allow for more rapid dose titration.
Conclusion
Metformin ER 500 mg tablets offer a viable alternative to IR formulations, providing comparable bioavailability and pharmacokinetics while improving patient adherence and satisfaction. The extended-release formulation ensures prolonged drug absorption, effective glycemic control, and reduced gastrointestinal side effects, making it a preferred choice for many patients with type 2 diabetes mellitus.
Sources and full results
Most relevant research papers on this topic